NEW YORK (GenomeWeb News) – MDS Pharma Services and Compendia Bioscience have collaborated to develop a pharmacogenomic platform for use in cancer patients and therapeutics research, MDS said today.
The new OncoPredictor combines MDS Pharma Services' OncoPanel, which offers high-content screening of up to 240 cancer cell lines for sensitivity to specific cancer drugs and drug combinations, with Compendia's Oncomine database. The Compendia database of cancer genomic profiles and its analysis application provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from 27,000 reference patients.
The combined OncoPredictor system will analyze drug sensitivity and resistance of novel drugs and drug combinations for cancer research.
"Our pharmaceutical and biotechnology clients seek to determine the efficacy of their compounds across cancer genotypes and patient phenotypes," Compendia's CEO Dan Rhodes said in a statement. "OncoPredictor will help provide the answer with technology for information-based lead selection, predictive in vivo study design and biomarker development."